Clinical Handbook Of Psychotropic Drugs 25th Edition by Ric Procyshyn, Kalyna Bezchlibnyk-Butler, David Kim ISBN 0889376328 978-0889376328

Clinical Handbook Of Psychotropic Drugs 25th Edition by  Ric M. Procyshyn, Kalyna Z. Bezchlibnyk-Butler,  David D. Kim  – Ebook PDF Instant Download/Delivery:  0889376328, 978-0889376328
Full download Clinical Handbook Of Psychotropic Drugs 25th Edition after payment

Product details: 

ISBN 10:  0889376328 

ISBN 13: 978-0889376328

Author:  Ric M. Procyshyn, Kalyna Z. Bezchlibnyk-Butler,  David D. Kim 

Quick and comprehensive information on psychotropic drugs for adults.

Accurate and up-to-date
Comparison charts help decision-making
Icons with full color
Available both in print and online
Downloadable patient information sheets

More about this book
The Clinical Handbook of Psychotropic Drugs has become a standard reference and working tool for psychiatrists, psychologists, physicians, pharmacists, nurses, and other mental health professionals.

Independent, unbiased, up-to-date
Packed with unique, easy-to-read comparison charts and tables (dosages, side effects, pharmacokinetics, interactions…) for a quick overview of treatment options
Succinct, bulleted information on all classes of medication: on- and off-label indications, (US FDA, Health Canada), recommended dosages, US and Canadian trade names, side effects, interactions, pharmacodynamics, precautions in the young, the elderly, and pregnancy, nursing implications, and much more – all you need to know for each class of drug
Potential interactions and side effects summarized in comparison charts
With instantly recognizable icons and in full color throughout, allowing you to find at a glance all the information you seek
Clearly written patient information sheets available for download as printable PDF files

This book is a must for everyone who needs an up-to-date, easy-to-use, comprehensive summary of all the most relevant information about psychotropic drugs.
New in this edition

Antidepressants chapter includes a new section on the NMDA receptor antagonist/CYP2D6 inhibitor combination product (dextromethorphan/bupropion)
Antipsychotics updates include revised clozapine monitoring tables which now also contain monitoring requirements for patients with or without non-benign ethnic neutropenia
Mood Stabilisers sections on Lithium and Anticonvulsants extensively revised
Dementia chapter includes a new section on lecanemab, a new fast-track FDA-approved treatment for Alzheimer’s disease
Treatment of Substance Use Disorders includes revisions to buprenorphine dosing section that include a rapid micro-induction method (Bernese method) that allows treatment to start without waiting for patient to be in withdrawal
Unapproved treatments of Psychiatric Disorders, Natural Health Products, and Pharmacogenetics chapters all substantially revised
New formulations and trade names include: Auvelity (dextromethorphan/bupropion extended-release tablets), Invega Hafyera (paliperidone 6-monthly IM injection), Leqembi (lecanemab infusion), Subutex (buprenorphine sublingual tablets), Quviviq (daridorexant tablets)

Table of contents: 

Antidepressants
Selective Serotonin Reuptake Inhibitors (SSRIs)
Norepinephrine Dopamine Reuptake Inhibitor (NDRI)
Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)
Serotonin-2 Antagonists/Reuptake Inhibitors (SARIs)
Serotonin-1A Partial Agonist/Serotonin Reuptake Inhibitor (SPARI)
Serotonin Modulator and Stimulator (SMS)
Noradrenergic/Specific Serotonergic Antidepressant (NaSSA)
Nonselective Cyclic Antidepressants
Monoamine Oxidase Inhibitors
Reversible Inhibitor of MAO-A (RIMA)
Irreversible Monoamine Oxidase (A&B) Inhibitors (MAOIs)
Irreversible MAO-B Inhibitor
GABAA Receptor Positive Modulator
NMDA Receptor Antagonist
NMDA Receptor Antagonist/CYP2D6 Inhibitor
Effects of Antidepressants on Neurotransmitters/Receptors
Pharmacological Effects of Antidepressants on Neurotransmitters/Receptors
Frequency of Adverse Reactions to Antidepressants at Therapeutic Doses
Antidepressant Doses and Pharmacokinetics
Switching Antidepressants
Antidepressant Augmentation Strategies
Electroconvulsive Therapy (ECT)
Bright Light Therapy (BLT)
Repetitive Transcranial Magnetic Stimulation (rTMS)
Antipsychotics
First-Generation Antipsychotics/FGAs
Second-Generation Antipsychotics/SGAs
Third-Generation Antipsychotics/TGAs
5‑HT2A Inverse Agonist Antipsychotic
Effects of Antipsychotics on Neurotransmitters/Receptors
Pharmacological Effects of Antipsychotics on Neurotransmitters/Receptor Subtypes
Relative Tolerability Profiles of Antipsychotics
Frequency (%) of Adverse Reactions to Antipsychotics at Therapeutic Doses
Antipsychotic Doses and Pharmacokinetics (Oral and Short-Acting Injections)
Comparison of Long-Acting IM Antipsychotics
Switching Antipsychotics
Antipsychotic Augmentation Strategies
Antipsychotic-Induced Extrapyramidal Side Effects and Their Management
Extrapyramidal Adverse Effects of Antipsychotics
Treatment Options for Extrapyramidal Side Effects
Effects on Acute Extrapyramidal Symptoms and Tardive Dyskinesia
Comparison of Agents for Treating Acute Extrapyramidal Side Effects and Tardive Dyskinesia
Doses and Pharmacokinetics of Agents for Treating Acute Extrapyramidal Side Effects and Tardive Dyskinesia
Anxiolytic (Antianxiety) Agents
Benzodiazepines
Comparison of the Benzodiazepines
Buspirone
Hypnotics/Sedatives
Comparison of Hypnotics/Sedatives
Mood Stabilizers
Lithium
Anticonvulsants
Comparison of Anticonvulsants
Frequency of Adverse Reactions to Mood Stabilizers at Therapeutic Doses
Drugs for ADHD
Psychostimulants
Selective Norepinephrine Reuptake Inhibitors
Comparison of Drugs for ADHD
α2 agonists
Augmentation Strategies in ADHD
Drugs for Treatment of Dementia
Cholinesterase Inhibitors
Memantine
Lecanemab
Comparison of Drugs for Treatment of Dementia
Sex-Drive Depressants
Comparison of Sex-Drive Depressants
Drugs of Abuse
Alcohol
Stimulants
Hallucinogens and Cannabinoids
Opioids
Inhalants/Aerosols
Gamma-hydroxybutyrate (GHB)/Sodium Oxybate
Flunitrazepam (Rohypnol)
Nicotine/Tobacco
Treatment of Substance Use Disorders
Acamprosate
Disulfiram
Naltrexone
Buprenorphine
Methadone
Pharmacotherapy for Nicotine/Tobacco Use Disorder
Comparison of Treatments for Nicotine/Tobacco Use Disorder
Unapproved Treatments of Psychiatric Disorders
Adrenergic Agents
Anti-inflammatory Agents
Cannabinoids
Dopaminergic Agents
GABA Agents/Anticonvulsants
Hormones
NMDA Agents (Glutamatergic Modulators)
5‑HT3 Antagonists
Miscellaneous
Natural Health Products
Ginkgo Biloba
Kava Kava
Melatonin
Omega-3 Polyunsaturated Fatty Acids
S-Adenosyl-L-Methionine (SAMe)
St. John’s Wort
Valerian
Vitamins
Pharmacogenetic Information for Common Psychotropic Drugs
Pharmacogenetic Effects
Glossary
Drug Use in Pregnancy and Effects on Breast Milk
Patient Information Sheets – Overview
Index of Drugs
Patient Information Sheets – Printable Handouts
Acamprosate
Anticonvulsant Mood Stabilizers
Antiparkinsonian Drugs
Antipsychotic Drugs
Anxiolytics
Atomoxetine
BLT
Buprenorphine
Bupropion
Buspirone
Clonidine
Clozapine
Cyclic Antidepressants
Deutetrabenazine
Dextromethorphan/Bupropion Combination
Disulfiram
Dementia Treatment
ECT
Esketamine
Hypnotics
Lithium
MAOI
Methadone
Mirtazapine
Moclobemide
Naltrexone
Pimavanserin
Psychostimulants
rTMS
SARI
Transdermal Selegiline
Sex-Drive Depressants
SNRI
SSRI
Valbenazine
Vilazodone
Viloxazine
Vortioxetine

People also search for:

clinical handbook of psychotropic drugs 25th edition
    
clinical handbook of psychotropic drugs pdf free download
    
clinical handbook of psychotropic drugs 25th edition pdf
    
clinical handbook of psychotropic drugs pdf
    
clinical handbook of psychotropic drugs online

Tags:

Ric Procyshyn,Kalyna Bezchlibnyk-Butler,David Kim,Clinical Handbook, Psychotropic Drugs